$31.32 Million in Sales Expected for Tabula Rasa Healthcare Inc. (TRHC) This Quarter
Analysts predict that Tabula Rasa Healthcare Inc. (NASDAQ:TRHC) will announce $31.32 million in sales for the current quarter, Zacks reports. Two analysts have made estimates for Tabula Rasa Healthcare’s earnings. The lowest sales estimate is $31.14 million and the highest is $31.50 million. Tabula Rasa Healthcare reported sales of $24.17 million during the same quarter last year, which indicates a positive year-over-year growth rate of 29.6%. The firm is scheduled to announce its next quarterly earnings results on Wednesday, November 8th.
On average, analysts expect that Tabula Rasa Healthcare will report full-year sales of $31.32 million for the current financial year, with estimates ranging from $117.80 million to $128.00 million. For the next year, analysts forecast that the firm will report sales of $178.89 million per share, with estimates ranging from $172.60 million to $184.30 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Tabula Rasa Healthcare.
Tabula Rasa Healthcare (NASDAQ:TRHC) last posted its quarterly earnings data on Monday, August 7th. The company reported $0.06 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.06. The company had revenue of $29.70 million during the quarter, compared to analyst estimates of $27.84 million. Tabula Rasa Healthcare had a negative net margin of 10.27% and a negative return on equity of 9.58%. The business’s revenue was up 32.6% on a year-over-year basis.
A number of equities analysts recently issued reports on the stock. Stifel Nicolaus reiterated a “buy” rating and set a $16.00 price objective on shares of Tabula Rasa Healthcare in a research report on Friday, July 14th. Chardan Capital assumed coverage on shares of Tabula Rasa Healthcare in a research report on Monday, July 10th. They set a “buy” rating and a $19.50 price objective for the company. UBS AG upped their price objective on shares of Tabula Rasa Healthcare from $18.00 to $25.00 and gave the stock a “buy” rating in a research report on Wednesday, August 30th. Wells Fargo & Company cut shares of Tabula Rasa Healthcare from an “outperform” rating to a “market perform” rating and upped their price objective for the stock from $17.00 to $21.00 in a research report on Thursday, September 7th. Finally, Robert W. Baird upped their price objective on shares of Tabula Rasa Healthcare from $17.00 to $18.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 8th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $20.71.
Shares of Tabula Rasa Healthcare (NASDAQ TRHC) opened at 26.07 on Tuesday. The stock’s 50 day moving average is $23.99 and its 200 day moving average is $23.99. Tabula Rasa Healthcare has a 12-month low of $10.39 and a 12-month high of $26.79. The firm’s market cap is $450.65 million.
In related news, insider Orsula V. Knowlton sold 8,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 19th. The shares were sold at an average price of $14.20, for a total transaction of $113,600.00. Following the completion of the transaction, the insider now directly owns 903,407 shares in the company, valued at approximately $12,828,379.40. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Over the last quarter, insiders have sold 24,000 shares of company stock valued at $428,080. 45.80% of the stock is owned by corporate insiders.
A number of hedge funds have recently added to or reduced their stakes in TRHC. Wellington Management Group LLP increased its position in Tabula Rasa Healthcare by 37.2% during the 1st quarter. Wellington Management Group LLP now owns 782,142 shares of the company’s stock worth $10,544,000 after purchasing an additional 212,164 shares in the last quarter. Paradigm Capital Management Inc. NY acquired a new position in Tabula Rasa Healthcare during the 2nd quarter worth approximately $1,165,000. Hood River Capital Management LLC increased its position in Tabula Rasa Healthcare by 7.5% during the 2nd quarter. Hood River Capital Management LLC now owns 825,225 shares of the company’s stock worth $12,420,000 after purchasing an additional 57,724 shares in the last quarter. Northern Trust Corp increased its position in Tabula Rasa Healthcare by 97.4% during the 2nd quarter. Northern Trust Corp now owns 95,862 shares of the company’s stock worth $1,443,000 after purchasing an additional 47,306 shares in the last quarter. Finally, Icon Advisers Inc. Co. acquired a new position in Tabula Rasa Healthcare during the 2nd quarter worth approximately $684,000. Institutional investors and hedge funds own 28.85% of the company’s stock.
Tabula Rasa Healthcare Company Profile
Tabula Rasa HealthCare, Inc (Tabula Rasa), formerly CareKinesis, Inc, is a provider of patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations and manage risk. The Company delivers its solutions through a suite of technology-enabled products and services for medication risk management, which includes bundled prescription fulfillment and adherence packaging services for client populations with complex prescription needs.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tabula Rasa Healthcare Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa Healthcare Inc. and related companies with MarketBeat.com's FREE daily email newsletter.